Related Experiment Video

Updated: Jun 16, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Pharmacotherapy for end-stage coronary artery disease

Neel R Sodha1, Louis M Chu, Munir Boodhwani

  • 1Beth Israel Deaconess Medical Center, Harvard Medical School, Department of Surgery, LMOB 9B, 110 Francis Street, Boston, MA 02215, USA.

Expert Opinion on Pharmacotherapy
|January 22, 2010
PubMed

Insights

Pharmacotherapy offers new hope for end-stage coronary artery disease (CAD) patients ineligible for invasive treatments. Augmenting the body's natural blood vessel growth (angiogenesis) shows promise for treating chronic heart ischemia.

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Pharmacology

Background:

  • Coronary artery disease (CAD) is a primary cause of death globally.
  • Many patients with advanced CAD lack options for surgical or catheter-based interventions.
  • This review focuses on pharmacotherapeutic strategies for end-stage CAD.

Purpose of the Study:

  • To review current pharmacotherapeutic interventions for end-stage coronary artery disease.
  • To explore novel approaches for managing patients with limited invasive treatment options.

Main Methods:

  • Comprehensive literature review.
  • Focus on therapeutic angiogenesis research from 1980 to 2009.

Main Results:

  • Overview of current therapeutic strategies for end-stage CAD.
  • Identification of promising pharmacologic targets.

Conclusions:

  • Therapeutic angiogenesis, particularly enhancing endogenous responses with growth factors, is a promising strategy.
  • This approach aims to improve blood supply in chronic myocardial ischemia.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...